Estabrook Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Estabrook Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,000	Closed	-$7.38K	–	337
2024 Q4	$7.38K	Hold	10,000	–	–	﹤0.01%	284
2024 Q3	$15.7K	Hold	10,000	–	–	﹤0.01%	255
2024 Q2	$16.8K	Hold	10,000	–	–	﹤0.01%	248
2024 Q1	$24K	Hold	10,000	–	–	﹤0.01%	241
2023 Q4	$15.3K	Hold	10,000	–	–	﹤0.01%	261
2023 Q3	$10.9K	Hold	10,000	–	–	﹤0.01%	278
2023 Q2	$22.9K	Hold	10,000	–	–	﹤0.01%	252
2023 Q1	$24.3K	Hold	10,000	–	–	﹤0.01%	256
2022 Q4	$19.1K	Hold	10,000	–	–	﹤0.01%	271
2022 Q3	$24K	Hold	10,000	–	–	﹤0.01%	252
2022 Q2	$18.6K	Hold	10,000	–	–	﹤0.01%	283
2022 Q1	$20.9K	Hold	10,000	–	–	﹤0.01%	276
2021 Q4	$39.4K	Buy	+10,000	New	+$48.6K	0.01%	246

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Estabrook Capital Management's LXRX Position: Q1 2025 in Review

Estabrook Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2025, closing a stake of 10,000 shares — an estimated $7.38K sold.

Estabrook Capital Management first reported a position in LXRX in Q4 2021 and held it in 13 quarters. The position peaked at $39.4K in Q4 2021. 127 funds tracked by Wall St. Rank hold LXRX as of Q1 2025.

Estabrook Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Estabrook Capital Management sold 10,000 Lexicon Pharmaceuticals shares in Q1 2025, an estimated $7.38K.
Estabrook Capital Management first reported a position in Lexicon Pharmaceuticals in Q4 2021 and held it in 13 quarters.
Estabrook Capital Management's Lexicon Pharmaceuticals position peaked at $39.4K in Q4 2021.
127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2025.

Based on Estabrook Capital Management's 13F filing for Q1 2025, filed 14 May 2025.